ArticleNature medicine2025

The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial.

Dan-Yun Ruan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.